search
Back to results

Endocare for Pelvic-perineal Pain Related to Endometriosis Used at Home

Primary Purpose

Endometriosis, Chronic Pain, Pelvic Pain

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Endocare
Digital control
Sponsored by
Lucine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endometriosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women over 18 years of age with diagnosed endometriosis (histology, imaging, clinical symptomatology) and/or adenomyosis.
  • Women with at least 2 consecutive days per month of endometriosis-related pelvic-perineal pain of moderate to severe intensity (NS ≥ 4):

    • Women without amenorrhea: pain around the onset of menstruation.
    • Women with amenorrhea: most intense pain of the month.

Exclusion Criteria:

  • Pregnant or nursing women.
  • Women participating, or who have participated, in a clinical interventional study within 30 days prior to inclusion.
  • Women with severe visual, auditory or cognitive impairment, color blindness, photosensitivity, epilepsy or motion sickness.
  • Women whose pain is occasional and not present at each menstrual period.
  • Women who have previously received virtual reality treatments.
  • Women under judicial protection, guardianship, curatorship, protective mandate.

Sites / Locations

  • Clinique Tivoli DucosRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Endocare

Digital control

Arm Description

Outcomes

Primary Outcome Measures

Pain intensity change
The mean change in pain intensity assessed by a numeric rating scale (pain intensity numerical scale) between the pre-treatment measurement and one hour after the use of Endocare treatment, compared to the digital control during the five days of treatment.The pain scale is a 11-point numeric scale (0=no pain; 10=unbearable pain).

Secondary Outcome Measures

Change in pain intensity
Change in pain intensity assessed by numeric scale. The pain scale is a 11-point numeric scale (0=no pain; 10=unbearable pain).
Change in pain relief
Change in pain relief assessed by Likert pain relief scale. Its a 5-point categorical scale (0: no relief, 1: slight relief, 2: moderate relief, 3: lots of relief and 4: complete relief)
Weighted average change in pain intensity
Weighted average change (based on number of treatments Endocare or control uses) in pain intensity assessed by numeric scale. The pain scale is a 11-point numeric scale (0=no pain; 10=unbearable pain).
Change in stress value
Change in stress assessed by Visual Analogue Scale (VAS). Visual Analogue Scale (VAS) consists of a small unmarked 100 mm ruler with ends labelled 'none' and 'as bad as possible'.
Change in fatigue value
Change in stress assessed by Visual Analogue Scale (VAS) and fatigue assessed by Pichot Scale. The Pichot scale evaluates 8 fatigue items ranging from 0 to 4 (0: not at all; 1: a little; 2: moderately; 3: a lot; 4: extremely)
Change in endometriosis-related quality of life
Change in endometriosis-related quality of life assessed by Endometriosis Health Profile (EHP-5). The EHP-5 consists of 11 items ranging from "never" to "always"
Assessment of the predictive value of dramatization and catastrophizing thoughts
Assessment of the predictive value of dramatization and catastrophizing thoughts assessed by Patient catastrophizing scale (PCS) coonsisting of 13 items ranging from 0 to 4 (0= not at all; 1= to a slight degree; 2= to a moderate degree; 3= to a great degree; 4 = all the time).
Pain relief treatments
Number, frequency and dosage of pain relief treatments assessed by patient diary
Assessment of satisfaction
Assessment of satisfaction by Likert scale. It is a 7-point Likert scale (1: extremely dissatisfied, 2: very dissatisfied, 3: dissatisfied, 4: neutral, 5: satisfied, 6: very satisfied, 7: extremely satisfied).
Assessment of Clinical Global Impression of Improvement
Assessment of Clinical Global Impression of Improvement by CGI scale. It is a 7-point scale (1=very much improved; 7=very much worse)
Incidence of adverse events and treatment adherence
Incidence of adverse events and treatment adherence collected by patients diary and phone

Full Information

First Posted
November 30, 2021
Last Updated
January 3, 2022
Sponsor
Lucine
Collaborators
Biotrial
search

1. Study Identification

Unique Protocol Identification Number
NCT05172492
Brief Title
Endocare for Pelvic-perineal Pain Related to Endometriosis Used at Home
Official Title
Efficacy of Endocare Treatment at Home on Pain in Women With Chronic Pelvic-perineal Pain Related to Endometriosis. EndoHome.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 7, 2021 (Actual)
Primary Completion Date
September 2022 (Anticipated)
Study Completion Date
September 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lucine
Collaborators
Biotrial

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Women with endometriosis experience recurrent pelvic-perineal pain impairing the quality of life, among other things. Endometriosis-related pain negatively impacts the sexual, family and work life. Apart from the usual painkillers, the doctor's current therapeutic arsenal is limited to hormonal contraceptives and surgery. As endometriosis-related treatments do not currently address all of the patients' problems, developing a new, effective, non-pharmaceutical treatment would make it possible to relieve the pain of these women. Endocare treatment consists of visual and auditory therapeutic procedures for pelvic-perineal pain in patients with endometriosis. Moreover, as Endocare is not a pharmacological molecule but a digital therapy, it would not increase the consumption of pharmacological agents. An analgesic effect of Endocare lasting several hours on chronic pelvic-perineal pain associated with endometriosis is expected. The effects of the treatment will be compare to a digital control also integrated in a virtual reality headset identical to the one distributing Endocare allowing to maintain the blindness to the patients and the investigator on the treatment received.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometriosis, Chronic Pain, Pelvic Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Endocare
Arm Type
Experimental
Arm Title
Digital control
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Endocare
Intervention Description
Endocare will be administred through a virtual reality headseat used one to twice a day.
Intervention Type
Device
Intervention Name(s)
Digital control
Intervention Description
Digital control will be administred through a virtual reality headseat used one to twice a day.
Primary Outcome Measure Information:
Title
Pain intensity change
Description
The mean change in pain intensity assessed by a numeric rating scale (pain intensity numerical scale) between the pre-treatment measurement and one hour after the use of Endocare treatment, compared to the digital control during the five days of treatment.The pain scale is a 11-point numeric scale (0=no pain; 10=unbearable pain).
Time Frame
Time points are before treatment (Time 0) and one hour after treatment (Time 1) during t five days (Day 1, Day 2, Day 3, Day 4, Day 5)
Secondary Outcome Measure Information:
Title
Change in pain intensity
Description
Change in pain intensity assessed by numeric scale. The pain scale is a 11-point numeric scale (0=no pain; 10=unbearable pain).
Time Frame
at wake-up and bedtime during the 5 days of treat (Day 1 to Day 5)
Title
Change in pain relief
Description
Change in pain relief assessed by Likert pain relief scale. Its a 5-point categorical scale (0: no relief, 1: slight relief, 2: moderate relief, 3: lots of relief and 4: complete relief)
Time Frame
At 1 hour (Time 1), 2 hours (Time 2) and 3 hours (Time 3) after treatment during the 5 days of treatment (Day 1 to Day 5)
Title
Weighted average change in pain intensity
Description
Weighted average change (based on number of treatments Endocare or control uses) in pain intensity assessed by numeric scale. The pain scale is a 11-point numeric scale (0=no pain; 10=unbearable pain).
Time Frame
from pre-treatment (Time 0) to 2 hours (Time 2) and 3 hours (Time 3) post-treatment during the 5 days of treatment (Day 1 to Day 5)
Title
Change in stress value
Description
Change in stress assessed by Visual Analogue Scale (VAS). Visual Analogue Scale (VAS) consists of a small unmarked 100 mm ruler with ends labelled 'none' and 'as bad as possible'.
Time Frame
at wake-up and bedtime during the 5 days of treatment (Day 1 to Day 5)
Title
Change in fatigue value
Description
Change in stress assessed by Visual Analogue Scale (VAS) and fatigue assessed by Pichot Scale. The Pichot scale evaluates 8 fatigue items ranging from 0 to 4 (0: not at all; 1: a little; 2: moderately; 3: a lot; 4: extremely)
Time Frame
at wake-up and bedtime during the 5 days of treatment (Day 1 to Day 5)
Title
Change in endometriosis-related quality of life
Description
Change in endometriosis-related quality of life assessed by Endometriosis Health Profile (EHP-5). The EHP-5 consists of 11 items ranging from "never" to "always"
Time Frame
At inclusion visit Day 0 and at through study completion (Day 6), an average of one week
Title
Assessment of the predictive value of dramatization and catastrophizing thoughts
Description
Assessment of the predictive value of dramatization and catastrophizing thoughts assessed by Patient catastrophizing scale (PCS) coonsisting of 13 items ranging from 0 to 4 (0= not at all; 1= to a slight degree; 2= to a moderate degree; 3= to a great degree; 4 = all the time).
Time Frame
At the inclusion visit Day 0
Title
Pain relief treatments
Description
Number, frequency and dosage of pain relief treatments assessed by patient diary
Time Frame
during the five days of treatment (Day 1 to Day 5) at bedtime
Title
Assessment of satisfaction
Description
Assessment of satisfaction by Likert scale. It is a 7-point Likert scale (1: extremely dissatisfied, 2: very dissatisfied, 3: dissatisfied, 4: neutral, 5: satisfied, 6: very satisfied, 7: extremely satisfied).
Time Frame
through study completion (Day 6), an average of one week
Title
Assessment of Clinical Global Impression of Improvement
Description
Assessment of Clinical Global Impression of Improvement by CGI scale. It is a 7-point scale (1=very much improved; 7=very much worse)
Time Frame
through study completion (Day 6), an average of one week
Title
Incidence of adverse events and treatment adherence
Description
Incidence of adverse events and treatment adherence collected by patients diary and phone
Time Frame
during the five days of treatment (Day 1 to Day 5)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women over 18 years of age with diagnosed endometriosis (histology, imaging, clinical symptomatology) and/or adenomyosis. Women with at least 2 consecutive days per month of endometriosis-related pelvic-perineal pain of moderate to severe intensity (NS ≥ 4): Women without amenorrhea: pain around the onset of menstruation. Women with amenorrhea: most intense pain of the month. Exclusion Criteria: Pregnant or nursing women. Women participating, or who have participated, in a clinical interventional study within 30 days prior to inclusion. Women with severe visual, auditory or cognitive impairment, color blindness, photosensitivity, epilepsy or motion sickness. Women whose pain is occasional and not present at each menstrual period. Women who have previously received virtual reality treatments. Women under judicial protection, guardianship, curatorship, protective mandate.
Facility Information:
Facility Name
Clinique Tivoli Ducos
City
Bordeaux
State/Province
Gironde
ZIP/Postal Code
33000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin Merlot, MD
Phone
+33650139254
Email
merlot.benjamin@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Endocare for Pelvic-perineal Pain Related to Endometriosis Used at Home

We'll reach out to this number within 24 hrs